India, July 30 -- Clearmind Medicine Inc. (CMND) on Thursday reported that Part A of its ongoing FDA-regulated Phase 1/2 trial met its primary endpoint of safety and tolerability for CMND-100 in the treatment of Alcohol Use Disorder (AUD).
CMND-100 is Clearmind's proprietary oral formulation of 5-methoxy-2-aminoindane (MEAI), a non-hallucinogenic neuroplastogen-derived compound intended to promote adaptive neuroplasticity while avoiding the perceptual effects associated with classical psychedelic therapies.
The company believes this profile could enable a more accessible treatment approach without requiring intensive clinical supervision or prolonged monitored treatment sessions.
The Phase 1/2 trial is a multinational, multicenter study ...